Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.52 |
| ▸ | PPARG | P37231 | 4/20 | 0.50 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 4/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25172771 | 0.87 | PPARA (0.48) | PPARAPPARGIDO1ACEPPARD | |
| SCHEMBL25172772 | 0.87 | PPARA (0.48) | PPARAPPARGIDO1ACEPPARD | |
| SCHEMBL26984477 | 0.87 | PPARA (0.48) | PPARAPPARGIDO1ACEPPARD | |
| SCHEMBL25178783 | 0.81 | PPARA (0.49) | PPARAPPARGIDO1ACEPPARD | |
| SCHEMBL2780551 | 0.80 | CTSS (0.51) | PPARAPPARGIDO1CTSSCTSK | |
| SCHEMBL2780552 | 0.80 | CTSS (0.51) | PPARAPPARGIDO1CTSSCTSK | |
| SCHEMBL31407349 | 0.80 | CTSS (0.51) | PPARAPPARGIDO1CTSSCTSK | |
| SCHEMBL13625093 | 0.80 | SLC18A3 (0.51) | PPARAPPARGIDO1ACEPPARD | |
| SCHEMBL31407680 | 0.78 | PPARA (0.44) | PPARAPPARGIDO1ACEPPARD | |
| SCHEMBL31407498 | 0.78 | PPARA (0.44) | PPARAPPARGIDO1ACEPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3663281-B1 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2022-12-28 | — | — | EP | disclosed |
| US-11319286-B2 | Heterocyclic compound and application thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-05-03 | — | — | US | disclosed |
| US-20200385346-A1 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-10 | — | — | US | disclosed |
| EP-3663281-A1 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2020-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319286-B2 | Heterocyclic compound and application thereof | HCRTR2, HCRTR1, NPY2R | PPARA 711/4885PPARG 950/4885HCRTR2 1/4885 |
| US-20200385346-A1 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | HCRTR2, HCRTR1, NPY2R | PPARA 711/4885PPARG 950/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.